Tearsheet

Bionano Genomics (BNGO)

Market Price (12/27/2025): $1.54 | Market Cap: $8.2 Mil
Sector: Health Care | Industry: Health Care Equipment

Bionano Genomics (BNGO)

Market Price (12/27/2025): $1.54
Market Cap: $8.2 Mil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -54%	Weak multi-year price returns 2Y Excs Rtn is -144%, 3Y Excs Rtn is -181%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -37 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -127%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18%	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more.		Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 19%
3			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -65%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -65%
4			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -480%
5			High stock price volatility Vol 12M is 113%
6			Key risks BNGO key risks include [1] a significant "going concern" risk stemming from a limited cash runway and substantial unprofitability, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -54%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more.
3	Weak multi-year price returns 2Y Excs Rtn is -144%, 3Y Excs Rtn is -181%
4	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18%
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -37 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -127%
6	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14%
7	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 19%
8	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -65%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -65%
9	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -480%
10	High stock price volatility Vol 12M is 113%
11	Key risks BNGO key risks include [1] a significant "going concern" risk stemming from a limited cash runway and substantial unprofitability, Show more.

Valuation, Metrics & Events

	12/27/25	2024	2023	2022	2021
Share Price CYE	$1.54	$17.30	$113.40	$876.00	$1,794.00
Market Cap CYE ($ Mil)	8.2	32.3	75.3	433.9	849.0
Total Debt ($ Mil)	17.2	6.9	9.6	11.7	10.7
Total Cash ($ Mil)	21.6	9.5	66.8	113.2	250.6
Enterprise Value ($ Mil)	3.8	39.2	84.9	445.6	859.7
Valuation Ratios
P/S TTM	0.3	0.7	1.8	15.2	46.0
P/EBIT TTM	-0.2	-0.2	-0.3	-3.2	-10.7
P/E TTM	-0.2	-0.2	-0.3	-3.2	-11.4
P/FCF TTM	-0.4	-0.3	-0.5	-3.3	-11.3
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.6
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/27/25	2024	2023
Share Price CYE	$1.54	$17.30	$113.40
Market Cap CYE ($ Mil)	8.2	32.3	75.3
Total Debt ($ Mil)	17.2	6.9	9.6
Total Cash ($ Mil)	21.6	9.5	66.8
Enterprise Value ($ Mil)	3.8	39.2	84.9
Valuation Ratios
P/S TTM	0.3	0.7	1.8
P/EBIT TTM	-0.2	-0.2	-0.3
P/E TTM	-0.2	-0.2	-0.3
P/FCF TTM	-0.4	-0.3	-0.5
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	BNGO	S&P 500
REVENUE GROWTH
Rev LTM ($ Bil)	0.0
Rev Chg Q	21.3%	7.3%
Rev Chg LTM	-13.8%	6.1%
Rev Chg 3Y Avg	5.1%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-127.5%	18.8%
CFO/Rev LTM	-65.0%	20.4%
Net Inc Mgn	-134.4%	13.1%
VALUATION	VERY LOW
P/S	0.3	3.3
P/CFO	-0.4	15.8
P/FCF	-0.4	20.7
P/E	-0.2	23.5
STABILITY	FAIR
Debt/Equity	2.09	0.21
Cash/Assets	0.27	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Nanochannel array flowcells sold	7233	6302025	Link
OGM System Installed Base	378	6302025	Link
New OGM system installations	7	6302025	Link

Upcoming
3/30/2026	Earnings Release	Rev: - EPS: -

BNGO Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

The stock of Bionano Genomics (BNGO) experienced a significant decline of approximately 59.7% from an estimated price of $3.77 on August 31, 2025, to $1.52 on December 26, 2025. Several key factors contributed to this downward movement:

1. Public Offering and Potential Dilution<br>

In September 2025, Bionano Genomics completed a public offering of common stock, which successfully raised $10 million in gross proceeds to bolster its balance sheet. While providing necessary capital, such offerings typically lead to the dilution of existing shares, which can exert downward pressure on the stock price as the ownership stake of current shareholders is reduced.

2. Negative Market Reaction to Q3 2025 Earnings<br>

Despite reporting seemingly positive financial results for the third quarter of 2025 on November 13, 2025, Bionano Genomics' stock experienced a notable downturn, closing down 7.5% on the day of the announcement. The company reported a 21% increase in total revenue year-over-year and a significant expansion in its non-GAAP gross margin to 46%. This negative market reaction, even with improved financials, suggests that investor expectations for growth or a clear path to profitability may not have been fully satisfied, or other underlying concerns continued to weigh on the stock.

Stock Movement Drivers

Fundamental Drivers

The -8.4% change in BNGO stock from 9/26/2025 to 12/26/2025 was primarily driven by a -55.1% change in the company's Shares Outstanding (Mil).

	9262025	12262025	Change
Stock Price ($)	1.66	1.52	-8.43%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	27.43	28.72	4.72%
P/S Multiple	0.21	0.28	35.65%
Shares Outstanding (Mil)	3.44	5.34	-55.13%
Cumulative Contribution			-36.26%

LTM = Last Twelve Months as of date shown

Market Drivers

9/26/2025 to 12/26/2025

	Return	Correlation
BNGO	-8.4%
Market (SPY)	4.3%	48.1%
Sector (XLV)	15.2%	26.2%

Fundamental Drivers

The -53.8% change in BNGO stock from 6/27/2025 to 12/26/2025 was primarily driven by a -98.1% change in the company's Shares Outstanding (Mil).

	6272025	12262025	Change
Stock Price ($)	3.29	1.52	-53.80%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	28.46	28.72	0.90%
P/S Multiple	0.31	0.28	-9.27%
Shares Outstanding (Mil)	2.69	5.34	-98.14%
Cumulative Contribution			-98.30%

LTM = Last Twelve Months as of date shown

Market Drivers

6/27/2025 to 12/26/2025

	Return	Correlation
BNGO	-53.8%
Market (SPY)	12.6%	11.0%
Sector (XLV)	17.0%	8.4%

Fundamental Drivers

The -88.3% change in BNGO stock from 12/26/2024 to 12/26/2025 was primarily driven by a -273.0% change in the company's Shares Outstanding (Mil).

	12262024	12262025	Change
Stock Price ($)	12.96	1.52	-88.27%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	33.33	28.72	-13.84%
P/S Multiple	0.56	0.28	-49.22%
Shares Outstanding (Mil)	1.43	5.34	-273.03%
Cumulative Contribution			-175.70%

LTM = Last Twelve Months as of date shown

Market Drivers

12/26/2024 to 12/26/2025

	Return	Correlation
BNGO	-88.3%
Market (SPY)	15.8%	11.5%
Sector (XLV)	13.3%	2.0%

Fundamental Drivers

The -99.8% change in BNGO stock from 12/27/2022 to 12/26/2025 was primarily driven by a -10955.7% change in the company's Shares Outstanding (Mil).

	12272022	12262025	Change
Stock Price ($)	852.00	1.52	-99.82%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	25.89	28.72	10.94%
P/S Multiple	1.59	0.28	-82.22%
Shares Outstanding (Mil)	0.05	5.34	-10955.65%
Cumulative Contribution			-2241.14%

LTM = Last Twelve Months as of date shown

Market Drivers

12/27/2023 to 12/26/2025

	Return	Correlation
BNGO	-98.8%
Market (SPY)	48.0%	19.7%
Sector (XLV)	18.2%	11.0%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
BNGO Return	148%	-3%	-51%	-87%	-85%	-91%	-100%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
BNGO Win Rate	42%	17%	42%	33%	25%	33%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
BNGO Max Drawdown	-79%	-3%	-59%	-91%	-90%	-92%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	BNGO	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-99.2%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	12257.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-79.6%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	389.0%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	271 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-93.7%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	1483.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	459 days	120 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

Bionano Genomics's stock fell -99.2% during the 2022 Inflation Shock from a high on 2/16/2021. A -99.2% loss requires a 12257.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Bionano Genomics (BNGO)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

AI Analysis | Feedback

The Illumina for large-scale structural changes in DNA.
If Illumina provides the alphabet of the genome, Bionano provides the blueprint of its architecture.
The Foundation Medicine for structural genomics.

AI Analysis | Feedback

Saphyr System: An instrument platform utilized for high-resolution optical genome mapping (OGM) to detect structural variants in the genome.
OGM Reagents and Consumables: Kits and chips essential for preparing DNA samples and running OGM assays on the Saphyr system.
Bionano Access and Solve Software: Proprietary software solutions for data analysis, visualization, and interpretation of OGM results.
Clinical OGM Solutions: Specific OGM applications and assays designed for detecting structural variants in various clinical and research areas, including prenatal, postnatal, and cancer diagnostics.

AI Analysis | Feedback

Bionano Genomics (BNGO) develops and markets the Saphyr system, a platform for optical genome mapping (OGM) used for structural variant detection in genomics research and clinical applications. As such, the company primarily sells its products and services to other organizations rather than directly to individuals.

Bionano Genomics does not publicly disclose a list of its specific major customers by name, nor does it typically identify individual companies (with stock symbols) as major customers. This is common practice for companies selling scientific instrumentation and consumables to a broad base of research and clinical laboratories. Instead, their customer base consists of various types of institutions and organizations globally.

The primary categories of customers that Bionano Genomics serves include:

Academic and Research Institutions: This category includes universities, academic medical centers, and government-funded research laboratories worldwide. These institutions utilize the Saphyr system for basic science research, translational studies, and large-scale genomics projects aimed at understanding diseases and biological processes.
Clinical Diagnostic Laboratories: Both private and public clinical labs adopt Bionano's technology to enhance their diagnostic and prognostic testing capabilities for various conditions, including genetic disorders, rare diseases, and different types of cancer. These labs aim to integrate OGM into their routine clinical workflows.
Biopharmaceutical Companies: Companies engaged in drug discovery, development, and therapeutic research, especially those focused on genomics, gene therapy, and precision medicine, utilize the Saphyr system for detailed genomic analysis critical to their R&D pipelines.
Contract Research Organizations (CROs): CROs that offer genomics services to pharmaceutical, biotechnology, and academic clients may incorporate Bionano's technology to provide advanced structural variant analysis as part of their service offerings.

AI Analysis | Feedback

null

AI Analysis | Feedback

Erik Holmlin, PhD, President and Chief Executive Officer

Dr. Erik Holmlin has served as the CEO and President of Bionano Genomics since January 2011. He has over two decades of experience in the life science and healthcare industries. Dr. Holmlin founded GeneOhm Sciences, Inc., in 2001, and orchestrated its acquisition by Becton Dickinson in 2006. He also served as an Entrepreneur in Residence at Domain Associates, LLC, a leading life-science venture capital firm. His prior experience includes CEO at GenVault Corporation, Chief Commercial Officer at Exiqon A/S, and Vice President of Marketing and Development at Becton Dickinson.

Christopher Stewart, Former Chief Financial Officer

Christopher Stewart served as Bionano Genomics' Chief Financial Officer from September 2020 to September 2023. He brings over 20 years of financial management experience to his role. Prior to Bionano, he was Head of the Maxwell Ultracapacitors business unit at Tesla after Maxwell Technologies was acquired by Tesla. He also served as Vice President of Finance & Information Technology at Maxwell Technologies (a public company), Vice President of Finance at Entropic Communications (a public company), and Chief Financial Officer of V-ENABLE (now xAD), a leader in targeted mobile advertising. Stewart has demonstrated extensive mergers and acquisition experience.

Mark Oldakowski, Chief Operating Officer

Mark Oldakowski has a 20-year history of success in developing systems for the life sciences and medical device industries. Before joining Bionano Genomics, he led a global team at Brooks Life Science Systems in the development of sample analyzers, high-throughput screening solutions, and biobank systems. He also held roles at Affymetrix, where he launched an array platform widely used for genomics applications, Siemens Healthcare Diagnostics, and Life Technologies (formerly Applied Biosystems), where he was involved in developing systems for real-time PCR, sequencing, and sample preparation.

Alka Chaubey, PhD, FACMG, Chief Medical Officer

Dr. Alka Chaubey joined Bionano as its first Chief Medical Officer, effective August 31, 2020. She is double board-certified in clinical cytogenetics/genomics and clinical molecular genetics/genomics by the American Board of Medical Genetics and Genomics (ABMGG). Dr. Chaubey has nearly 20 years of scientific and clinical experience, including serving as the Head of Cytogenomics for PerkinElmer Genomics and for Vanadis, where she led the development and launch of several innovative products. She was also the Director of the Cytogenomics Laboratory at the Greenwood Genetic Center.

Jason Priar, Chief Commercial Officer

Jason Priar joined Bionano Genomics as Chief Commercial Officer in June 2021. He is a seasoned sales leader with experience scaling businesses from early stage to hundreds of millions in revenue. His background includes sales leadership positions at GeneDx, Sema4, and PerkinElmer Genomics, where he was responsible for sales, marketing, customer support, and managed care across various regions. Under his leadership at GeneDx, revenue grew from $8 million to over $225 million.

AI Analysis | Feedback


  
    Key Risks to Bionano Genomics (BNGO)
    
      
        Cash and Capital / Profitability: Bionano Genomics faces significant financial risks due to its substantial accumulated deficit, reported to be over $703.2 million as of June 30, 2025, and continued negative cash flow from operations. The company's cash and equivalents of $31.8 million at the end of Q3 2025 provide a cash runway only into the third quarter of 2026, making it a "going concern" risk. Despite efforts to reduce operating expenses and improve gross margins, the company is not yet profitable, with a forecasted earnings per share (EPS) loss of approximately -$6.23 for fiscal year 2025. This ongoing cash burn necessitates a reliance on equity to fund operations, leading to historical and potential future share dilution.
      
      
        Slow Adoption of Optical Genome Mapping (OGM) Technology / Revenue Challenges: The growth of Bionano's business is heavily dependent on the adoption and utilization of its Optical Genome Mapping (OGM) systems and associated high-margin consumables. However, the company has experienced slow growth in its installed base, with only 7 new OGM systems installed in Q3 2025, resulting in a net increase of just 3 to a total of 384 systems. This slow adoption limits the pool of customers purchasing consumables and contributes to challenges in revenue generation, including a reported decline in total revenue and flowcell sales volume. Analysts also point to a potentially small total addressable market (TAM) and a market not fully ready to embrace OGM technology, which could hinder the company's ability to create shareholder value. Additionally, slow clinical guideline adoption and reimbursement uncertainty threaten revenue acceleration.
      
      
        Technological Risk / Competition: Bionano Genomics operates in a rapidly evolving genomics landscape, facing high technological risk from both current and potential competitors. Competitive pressures, along with lagging research budgets and slow global market integration, could limit the company's growth prospects even as it attempts to increase software and consumables adoption.

AI Analysis | Feedback

The rapid advancements and increasing adoption of long-read sequencing technologies, particularly from companies like Pacific Biosciences (PacBio) and Oxford Nanopore Technologies (ONT). These platforms are continuously improving their ability to detect a broad spectrum of structural variants (SVs) with high accuracy, increasing throughput, and decreasing cost per genome. As long-read sequencing becomes more cost-effective and integrated into clinical and research workflows for comprehensive genome analysis, it directly encroaches upon Bionano Genomics' core value proposition of identifying large structural variants, potentially diminishing the unique necessity or market share of Optical Genome Mapping (OGM) as a standalone or primary solution for SV detection.

AI Analysis | Feedback

The addressable markets for Bionano Genomics' (BNGO) main products and services are substantial, primarily driven by the demand for advanced genomic analysis in research and clinical diagnostics.

Optical Genome Mapping (OGM)

The global optical genome mapping market was valued at approximately USD 131.50 million in 2023. It is estimated to reach USD 883.50 million by 2032, demonstrating a compound annual growth rate (CAGR) of 24.10% during the forecast period from 2024 to 2032.
North America held the largest share of the global optical genome mapping market in 2023, accounting for 45.07%.
Bionano's management has previously estimated its total addressable market for optical genome mapping capabilities to be USD 10 billion.

Genetic Testing and Diagnostic Services

Rare Disease Genetic Testing Market: The global rare disease genetic testing market is projected to grow from USD 918.94 million in 2023 to approximately USD 3,051.6 million by 2032, at a CAGR of 13.1% during the forecast period from 2022 to 2032.
Prenatal and Newborn Genetic Testing Market: The global prenatal and newborn genetic testing market was valued at USD 8.1 billion in 2024. This market is anticipated to grow to USD 26.8 billion by 2034, with a CAGR of 12.8%.
- Specifically, the U.S. prenatal and newborn genetic testing market reached USD 3.8 billion in 2024.
- Another report projects the global prenatal testing market to grow from USD 9.8 billion in 2022 to USD 19.8 billion in 2028, at a CAGR of 12.6%.
First-line genetic testing for Autism Spectrum Disorder (ASD) and other Neurodevelopmental Disorders (NDDs) (U.S.): Bionano Genomics has estimated the serviceable addressable market (SAM) in the United States for its Lineagen FirstStepDx PLUS testing to be between USD 1.7 billion and USD 2.2 billion.

AI Analysis | Feedback

Bionano Genomics (BNGO) is positioning itself for future revenue growth over the next two to three years through several key drivers, as indicated by recent company reports and analyst insights:

Increased Utilization of Optical Genome Mapping (OGM) Systems and Consumables: Bionano is strategically shifting its focus from merely increasing the installed base of its Saphyr systems to driving higher utilization among existing and new "routine users." This strategy aims to boost the sales of high-margin consumables, such as nanochannel array flowcells, which are directly linked to the number of genomes analyzed. For example, flowcell sales increased by 17% in Q2 2025 year-over-year, and consumables and software revenue grew 16% in the same quarter, representing 73% of product revenue. The company anticipates the installed base of OGM systems to reach 325 by the end of 2023, and has raised its expectations for new OGM installations in 2025 to 20-25 systems.
Expansion of VIA Software Platform Adoption: The VIA software is considered a crucial component of Bionano's digital pathology strategy and a gold standard for copy number variation (CNV) analysis for microarrays and sequencing. Bionano is actively driving the adoption of its VIA software, which streamlines the visualization, interpretation, annotation, and reporting of genetic variants. This expansion is expected to drive recurring revenue as customers increasingly integrate VIA into their genomic analysis workflows, even for data from other long-read sequencing technologies.
Favorable Reimbursement Landscape and Clinical Market Penetration: The issuance of Category I CPT codes for optical genome mapping (OGM), particularly for constitutional disorders and hematologic malignancies, is a significant catalyst for future revenue growth. These codes are expected to pave the way for more routine use of OGM in cytogenetics by facilitating reimbursement, making the technology more accessible and attractive to clinical laboratories. The company believes this progress will accelerate OGM adoption in the clinical market, potentially displacing older methods.
Technological Enhancements and Workflow Improvements for OGM: Continuous innovation and improvements to the OGM workflow are expected to drive adoption and utilization. The acquisition of Purigen Biosystems, for instance, is anticipated to accelerate OGM adoption by enhancing Bionano's ultra-high molecular weight (UHMW) DNA sample preparation workflow. Additionally, the positive reception and first-wave deployments of the Stratus compute are expected to foster further growth in user numbers across the United States and Europe by making OGM easier to implement and use, and capable of processing substantially more samples.

AI Analysis | Feedback

Share Issuance

In January 2021, Bionano Genomics announced the pricing of an underwritten public offering of 33,333,350 shares of its common stock at $6.00 per share, expecting to generate approximately $200 million in gross proceeds.
In October 2023, Bionano Genomics completed an $80 million financing round and ended the year with $102.3 million in cash and securities.
Bionano Genomics completed a registered direct offering in January 2025, raising $10 million through the sale of 39,682,540 shares of common stock and warrants at $0.252 per share, with potential for an additional $10 million if warrants are fully exercised. In September 2025, the company closed another public offering, raising approximately $10 million in gross proceeds from 5,000,000 shares at $2.00 per share and accompanying warrants, with the potential for an additional $20 million if warrants are fully exercised.

Outbound Investments

In August 2020, Bionano Genomics acquired Lineagen Inc., a genetic diagnostic company specializing in pediatric neurodevelopmental disorders, for approximately $9.6 million. The consideration included 6,167,510 shares of Bionano's common stock, approximately $1.7 million in cash, and the assumption of about $2.9 million in liabilities. Bionano also paid approximately $1.1 million to satisfy outstanding principal and accrued interest of a Paycheck Protection Program loan issued to Lineagen.

Capital Expenditures

Bionano Genomics' cash flow statements indicate capital expenditures of approximately -$2.4 million in 2020.
In 2021, capital expenditures were approximately -$278.1 million.
For 2024, Bionano's free cash flow was -$70.77 million, and operating cash flow was -$70.67 million, with proceeds from offerings generally intended for general corporate purposes, including capital expenditures.

Better Bets than Bionano Genomics (BNGO)

Apple

NVDA (2.2%)

NVIDIA

		Best Bets In Health Care Sector
	BNGO	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	-0.2	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	-0.2	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	21.3%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	-13.8%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	5.1%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	-246.1%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Bionano Genomics Earnings Notes
2	How Low Can Bionano Genomics Stock Really Go?	Return

	Title
0	ARTICLES

Trade Ideas

Select ideas related to BNGO. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.1%	21.1%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-6.7%	-6.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	16.7%	16.7%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	11.8%	11.8%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for Bionano Genomics

Peers to compare with:

Financials

	BNGO	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Bionano .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	1.52	23.26	24.49	305.09	78.16	273.40	51.32
Mkt Cap	0.0	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	29	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	-37	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	-19	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	-81	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	-19	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	-80	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	BNGO	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Bionano .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	-13.8%	3.2%	13.8%	4.5%	8.9%	6.0%	5.2%
Rev Chg 3Y Avg	5.1%	-3.9%	6.5%	2.6%	3.7%	1.8%	3.2%
Rev Chg Q	21.3%	4.2%	14.4%	9.1%	7.5%	9.6%	9.4%
QoQ Delta Rev Chg LTM	4.7%	1.1%	3.7%	2.1%	1.8%	2.1%	2.1%
Op Mgn LTM	-127.5%	6.6%	4.8%	17.7%	22.5%	31.9%	12.1%
Op Mgn 3Y Avg	-280.5%	7.4%	7.2%	16.4%	24.2%	30.8%	11.9%
QoQ Delta Op Mgn LTM	57.4%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.2%
CFO/Rev LTM	-65.0%	6.7%	8.5%	20.6%	23.8%	26.6%	14.6%
CFO/Rev 3Y Avg	-242.7%	6.8%	12.7%	21.4%	26.1%	28.4%	17.1%
FCF/Rev LTM	-65.0%	5.1%	1.8%	18.1%	22.1%	23.5%	11.6%
FCF/Rev 3Y Avg	-246.1%	5.5%	4.6%	18.6%	24.6%	25.6%	12.1%

Valuation

	BNGO	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Bionano .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	0.0	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	0.3	0.4	1.0	4.4	5.4	10.0	2.7
P/EBIT	-0.2	6.8	19.9	25.1	22.5	31.3	21.2
P/E	-0.2	8.6	572.7	36.0	29.9	41.0	33.0
P/CFO	-0.4	5.9	11.2	21.1	22.5	37.5	16.2
Total Yield	-475.6%	14.1%	2.3%	5.0%	5.4%	2.8%	3.9%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	-189.4%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	2.1	0.5	0.7	0.2	0.1	0.0	0.4
Net D/E	-0.5	0.3	0.6	0.2	0.0	0.0	0.1

Returns

	BNGO	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Bionano .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	-16.0%	-1.8%	14.4%	0.6%	2.7%	-1.5%	-0.4%
3M Rtn	-8.4%	-11.9%	2.7%	7.9%	17.0%	7.1%	4.9%
6M Rtn	-53.8%	-4.0%	34.5%	6.6%	15.2%	36.3%	10.9%
12M Rtn	-88.3%	-27.3%	14.2%	39.2%	33.7%	6.0%	10.1%
3Y Rtn	-99.8%	-3.8%	67.7%	139.0%	79.5%	113.4%	73.6%
1M Excs Rtn	-15.1%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-3.0%
3M Excs Rtn	-12.7%	-16.2%	-1.7%	3.6%	12.7%	2.8%	0.6%
6M Excs Rtn	-66.1%	-16.3%	22.3%	-5.7%	3.0%	24.0%	-1.3%
12M Excs Rtn	-103.4%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	-4.6%
3Y Excs Rtn	-181.2%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

FDIC Bank Data

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/13/2025	3/31/2025	3/5/2024	3/9/2023	3/1/2022	3/23/2021	3/10/2020
Key Financials
Total Revenue	29	31	36	28	18	9	10
EBITDA	-32	-95	-222	-121	-74	-37	-26
Operating Income	-37	-76	-137	-132	-77	-39	-26
Net Income	-39	-112	-232	-133	-72	-41	-30
EPS	-15.52	-88.13	-408.60	-274.80	-156.00	-234.00	-1194.00
Growth Rates
Total Revenue Growth	-13.8%	-14.8%	29.9%	54.6%	111.5%	-16.1%	-15.6%
EBITDA Growth	73.6%	56.9%	-83.7%	-63.3%	-99.2%	-40.6%	-67.2%
Operating Income Growth	58.7%	44.4%	-4.2%	-70.8%	-100.0%	-49.0%	-26.7%
Net Income Growth	71.6%	51.8%	-75.3%	-83.1%	-76.2%	-37.9%	-61.2%
Margins
EBITDA Margin	-111.9%	-309.9%	-613.4%	-433.7%	-410.7%	-436.1%	-260.4%
Operating Income Margin	-127.5%	-247.8%	-380.0%	-473.7%	-428.8%	-453.4%	-255.4%
Net Income Margin	-134.4%	-364.0%	-643.7%	-476.9%	-402.8%	-483.4%	-294.3%
Cash & Debt
Total Cash	22	9	67	113	251	38	17
Total Debt	17	7	10	12	11	16	20
Net Debt / (Cash)	-4	-3	-57	-102	-240	-22	3
Cash Flows
Net Cash from Operations	-19	-69	-125	-125	-72	-38	-30
Free Cash from Operations	-19	-69	-127	-128	-73	-38	-30
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/13/2025	8/14/2025	5/14/2025	3/31/2025	11/14/2024	8/7/2024	5/8/2024	3/5/2024	11/8/2023	8/9/2023	5/9/2023	3/9/2023
Key Financials Quarterly
Total Revenue	7	7	6	8	6	8	9	11	9	9	7	8
Ebitda	-6	-4	-6	-17	-38	-13	-27	-44	-109	-35	-34	-34
Operating Income	-9	-8	-8	-12	-23	-16	-26	-24	-36	-39	-38	-38
Net Income	-9	-7	-3	-20	-44	-16	-31	-44	-113	-39	-37	-39
EPS	-1.59	-1.99	-1.15	-10.79	-30.92	-14.41	-35.75	-57.60	-193.20	-74.40	-738.00	-78.09
Key Financials TTM
Total Revenue TTM	29	27	28	31	33	37	37	36	34	32	30	28
Ebitda TTM	-32	-64	-74	-95	-122	-193	-215	-222	-212	-132	-127	-121
Operating Income TTM	-37	-51	-59	-76	-89	-102	-125	-137	-151	-147	-140	-132
Net Income TTM	-39	-74	-84	-112	-136	-204	-227	-232	-227	-147	-140	-133
Growth Rates Quarterly
Total Revenue Growth	21.3%	-13.4%	-26.4%	-23.9%	-34.8%	-10.3%	18.3%	30.5%	29.0%	29.9%	30.2%	30.4%
EBITDA Growth	84.8%	71.9%	79.4%	60.8%	65.2%	62.3%	19.8%	-28.0%	-271.6%	-19.4%	-22.3%	-26.9%
Operating Income Growth	62.3%	50.6%	67.5%	51.3%	37.0%	59.7%	31.2%	35.5%	-11.8%	-22.3%	-26.4%	-30.4%
Net Income Growth	80.8%	57.7%	90.1%	54.1%	60.7%	58.3%	15.4%	-13.5%	-253.9%	-21.0%	-23.9%	-68.5%
Margins Quarterly
EBITDA Margin	-77.9%	-55.8%	-86.7%	-208.9%	-623.2%	-172.2%	-309.1%	-405.7%	-1167.4%	-409.3%	-455.6%	-413.6%
Operating Income Margin	-115.9%	-115.8%	-131.1%	-144.6%	-372.6%	-203.4%	-297.0%	-225.8%	-385.6%	-453.0%	-510.4%	-456.8%
Net Income Margin	-115.4%	-101.8%	-48.0%	-246.5%	-728.6%	-208.8%	-358.3%	-409.4%	-1208.0%	-449.2%	-500.7%	-470.8%
Cash & Debt
Total Cash	22	16	18	9	23	19	53	67	64	77	96	113
Total Debt	17	20	18	7	22	28	38	10	10	11	11	12
Net Debt / (Cash)	-4	3	0	-3	-1	9	-15	-57	-53	-66	-85	-102
Cash Flows Quarterly
FCF from Operations	-6	-3	-3	-7	-13	-21	-28	-30	-26	-37	-32	-35
Cash Flows TTM
FCF from Operations TTM	-19	-26	-44	-69	-92	-105	-121	-125	-130	-133	-125	-125
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-4.5%	-4.2%	-4.5%	-6.5%	-12.5%	-8.8%	-15.3%	-15.6%	-23.8%	-27.4%	-28.4%	-30.2%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-4.8%	-6.7%	-7.9%	-10.5%	-12.3%	-14.2%	-18.4%	-22.1%	-25.0%	-25.6%	-26.2%	-26.5%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Product revenue	27	20	13	6	9
Service and other	9	7	5	2	1
Total	36	28	18	9	10

Price Behavior

Price Behavior

Market Price	$1.52
Market Cap ($ Bil)	0.0
First Trading Date	09/21/2018
Distance from 52W High	-92.0%
	50 Days	200 Days
DMA Price	$1.69	$2.92
DMA Trend	down	down
Distance from DMA	-10.0%	-47.9%
	3M	1YR
Volatility	58.5%	113.8%
Downside Capture	214.05	207.04
Upside Capture	129.08	-35.85
Correlation (SPY)	46.7%	11.3%

BNGO Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	2.50	2.16	1.13	0.85	0.61	1.50
Up Beta	3.19	1.42	-0.70	-0.42	0.89	1.14
Down Beta	6.34	4.38	2.05	2.30	-0.02	0.61
Up Capture	194%	166%	-78%	-29%	-19%	32%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	8	19	27	54	99	297
Down Capture	167%	136%	283%	183%	141%	112%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	10	21	32	62	134	422

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of BNGO With Other Asset Classes (Last 1Y)
	BNGO	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-87.0%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.3%
Annualized Volatility	113.4%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	-1.26	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		2.2%	11.5%	4.6%	7.4%	9.8%	6.5%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of BNGO With Other Asset Classes (Last 5Y)
	BNGO	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-65.7%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	123.7%	14.5%	17.1%	15.5%	18.7%	18.9%	48.7%
Sharpe Ratio	-0.36	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		18.4%	25.3%	7.3%	5.4%	19.7%	15.6%

Based On 10-Year Data

		Comparison of BNGO With Other Asset Classes (Last 10Y)
	BNGO	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-66.5%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	196.4%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	-0.05	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		9.4%	12.4%	4.4%	3.8%	10.6%	6.1%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	956,130
Short Interest: % Change Since 11302025	-12.8%
Average Daily Volume	210,076
Days-to-Cover Short Interest	4.55
Basic Shares Quantity	5,338,000
Short % of Basic Shares	17.9%

Returns Analyses

	Title
0	How Low Can Bionano Genomics Stock Really Go?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/13/2025	3.4%	1.4%	6.8%
8/14/2025	-5.3%	28.7%	-13.7%
3/31/2025	11.1%	5.7%	43.0%
11/13/2024	-7.6%	-24.4%	-13.4%
8/7/2024	-6.7%	-2.5%	2.7%
3/5/2024	1.7%	-10.9%	-17.1%
11/8/2023	-2.2%	0.7%	8.1%
8/9/2023	-3.4%	-25.3%	-18.3%
...
SUMMARY STATS
# Positive	7	8	7
# Negative	12	11	12
Median Positive	2.6%	5.7%	8.1%
Median Negative	-7.1%	-11.9%	-17.7%
Max Positive	11.1%	43.8%	43.0%
Max Negative	-32.3%	-57.7%	-75.7%

	Forward Returns
11/13/2025	3.4%	1.4%	6.8%
8/14/2025	-5.3%	28.7%	-13.7%
3/31/2025	11.1%	5.7%	43.0%
11/13/2024	-7.6%	-24.4%	-13.4%
8/7/2024	-6.7%	-2.5%	2.7%
3/5/2024	1.7%	-10.9%	-17.1%
11/8/2023	-2.2%	0.7%	8.1%
8/9/2023	-3.4%	-25.3%	-18.3%
3/9/2023	-4.0%	-8.0%	-18.4%
11/3/2022	0.4%	5.7%	-12.3%
8/4/2022	2.6%	43.8%	-1.7%
3/1/2022	0.5%	-18.1%	25.0%
11/4/2021	-6.9%	-14.0%	-43.7%
8/4/2021	6.5%	3.1%	1.7%
3/23/2021	-11.2%	-7.8%	-28.8%
11/12/2020	-9.5%	-11.9%	-12.8%
8/13/2020	-8.1%	-10.7%	-28.2%
5/14/2020	-7.3%	6.8%	30.5%
3/5/2020	-32.3%	-57.7%	-75.7%
SUMMARY STATS
# Positive	7	8	7
# Negative	12	11	12
Median Positive	2.6%	5.7%	8.1%
Median Negative	-7.1%	-11.9%	-17.7%
Max Positive	11.1%	43.8%	43.0%
Max Negative	-32.3%	-57.7%	-75.7%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11132025	10-Q 9/30/2025
6302025	8142025	10-Q 6/30/2025
3312025	5142025	10-Q 3/31/2025
12312024	3312025	10-K 12/31/2024
9302024	11142024	10-Q 9/30/2024
6302024	8072024	10-Q 6/30/2024
3312024	5082024	10-Q 3/31/2024
12312023	3052024	10-K 12/31/2023
9302023	11082023	10-Q 9/30/2023
6302023	8092023	10-Q 6/30/2023
3312023	5092023	10-Q 3/31/2023
12312022	3092023	10-K 12/31/2022
9302022	11032022	10-Q 9/30/2022
6302022	8042022	10-Q 6/30/2022
3312022	5052022	10-Q 3/31/2022
12312021	3012022	10-K 12/31/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Equipment Resources

MedTech Dive

MassDevice

Fierce Medical Devices

Medical Device and Diagnostic Industry

MD+DI

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Bionano Genomics (BNGO)

Market Price (12/27/2025): $1.54 | Market Cap: $8.2 MilSector: Health Care | Industry: Health Care Equipment

Bionano Genomics (BNGO)

Market Price (12/27/2025): $1.54Market Cap: $8.2 MilSector: Health CareIndustry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

BNGO Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Bionano Genomics (BNGO)

Key Risks to Bionano Genomics (BNGO)

Optical Genome Mapping (OGM)

Genetic Testing and Diagnostic Services

Interactive Breakdown

Better Bets than Bionano Genomics (BNGO)

INDUSTRY: Health Care Equipment

Higher Rev Chg LTM (Value for BNGO: -13.8%)

Higher Rev Chg 3Y Avg (Value for BNGO: 5.1%)

Higher Op Mgn LTM (Value for BNGO: -127.5%)

Higher CFO/Rev LTM (Value for BNGO: -65.0%)

Higher FCF/Rev LTM (Value for BNGO: -65.0%)

Higher Total Yield (Value for BNGO: -475.6%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for BNGO: 5.1% | 0.3x)

Higher Rev Chg LTM (Value for BNGO: -13.8%)

Higher Rev Chg 3Y Avg (Value for BNGO: 5.1%)

Higher Op Mgn LTM (Value for BNGO: -127.5%)

Higher CFO/Rev LTM (Value for BNGO: -65.0%)

Higher FCF/Rev LTM (Value for BNGO: -65.0%)

Higher Total Yield (Value for BNGO: -475.6%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for BNGO: 5.1% | 0.3x)

Higher Rev Chg LTM (Value for BNGO: -13.8%)

Higher Rev Chg 3Y Avg (Value for BNGO: 5.1%)

Higher Op Mgn LTM (Value for BNGO: -127.5%)

Higher CFO/Rev LTM (Value for BNGO: -65.0%)

Higher FCF/Rev LTM (Value for BNGO: -65.0%)

Higher Total Yield (Value for BNGO: -475.6%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Bionano Genomics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Market Price (12/27/2025): $1.54 | Market Cap: $8.2 Mil
Sector: Health Care | Industry: Health Care Equipment

Market Price (12/27/2025): $1.54
Market Cap: $8.2 Mil
Sector: Health Care
Industry: Health Care Equipment